Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
T. Kohno, L.T. Tam, R.B. Bass, S.R. Stevens, J.S. Louie.
Adalimumab and infliximab bind to Fc-receptor and C1q and generate immunoprecipitation: a different mechanism from etanercept.
ACR Meeting,
[2.]
P.J. Anderson.
Tumor necrosis factor inhibitors: clinical implications of their different inmunogenicity profiles.
Semin Arthritis Rheum, 34 (2005), pp. 19-22
[3.]
M.C. Genovese, J.M. Bathon, R.M. Fleischmann, L.W. Moreland, R.W. Martín, J.B. Withmore, et al.
Longterm safety, efficacy, and radiografic outcome with etanercept treatment in patients with early rheumatoid arthritis.
J Rheumatol, 32 (2005), pp. 7
[4.]
D. Van der Heidje, R. Landewé, L. Klareskog, V. Rodríguez-Valverde, L. Settas, R. Pedersen, et al.
Presentation and analisis of data on radiographic outcome in clinical trials. Experience from TEMPO study.
Arthritis Rheum, 52 (2005), pp. 49-60
[5.]
M.E. Weinblatt, M.C. Genovese, L.W. Moreland, J.M. Bathon, J.M. Kremer.
Efficacy and safety of over 8 years of etanercept therapy in North American patients with early and long-standing rheumatoid arthritis.
ACR Meeting, (2005), pp. 1703
[6.]
A. Singh, L. Klareskog, Pedersen., S. Fatenejad.
Results of patient-reported outcomes in A 3-year double-blind study of etanercept (Enbrel®) and methotrexate, alone and combined, in patients with active rheumatoid arthritis: TEMPO.
ACR Meeting, (2005), pp. 551
[7.]
L. Klareskog.
Comparison of etanercept and methotrexate.
Ann Rheum Dis, 64 (2005), pp. 50
[8.]
D. Van der Heijde.
Aspects of the radiological evaluation of rheumatoid arthritis.
Ann Rheum Dis, 64 (2005), pp. 408
[9.]
M.E. Weinblatt, M.C. Genovese, L.W. Moreland, J.M. Bathon, J.M. Kremer, R.M. Fleischmann, et al.
Efficacy and safety of over 7 years of etanenercept (Enbrel®) therapy in North American patients with early and long-standing rheumatoid arthritis.
ACR Meeting, (2004), pp. 356
[10.]
E.C. Keystone, S.H. Shiff, J.M. Kremer, F. Kafka, M. Lovy, T. De Vries, et al.
Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis.
Arthritis Rheum, 50 (2004), pp. 353-363
Copyright © 2006. Elsevier España S.L. Barcelona
